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The proteaseMALT1 is a key regulator of NF-kB signaling and a novel therapeutic
target in autoimmunity and cancer. Initial enthusiasm supported by preclinical re-
sults with MALT1 inhibitors was tempered by studies showing that germline
MALT1 protease inactivation in mice results in reduced regulatory T cells and le-
thal multi-organ inflammation due to expansion of IFN-g-producing T cells. How-
ever, we show that long-term MALT1 inactivation, starting in adulthood, is not
associated with severe systemic inflammation, despite reduced regulatory
T cells. In contrast, IL-2-, TNF-, and IFN-g-producing CD4+ T cells were strongly
reduced. Limited formation of tertiary lymphoid structures was detectable in
lungs and stomach, which did not affect overall health. Our data illustrate that
MALT1 inhibition in prenatal or adult life has a different outcome and that long-
term MALT1 inhibition in adulthood is not associated with severe side effects.
INTRODUCTION
The paracaspase MALT1 is an important player in innate and adaptive immune signaling (Ruland and
Hartjes, 2019). MALT1 is best known for its role in T cell receptor (TCR) signaling leading to nuclear factor
(NF)-kB-dependent gene expression, which mediates the activation and proliferation of conventional
T cells as well as the development of regulatory T cells (Tregs). Upon TCR triggering, MALT1 is activated
as part of the so-called CARD11/BCL10/MALT1 (CBM) complex, where MALT1 functions as a scaffolding
protein to recruit the E3 ubiquitin ligase TRAF6 and activate the IkB kinase complex, leading to NF-kB acti-
vation (Sun et al., 2004; Oeckinghaus et al., 2007; Lork et al., 2019). TCR engagement also activates MALT1
proteolytic activity, leading to the cleavage of specific substrates (Ruland and Hartjes, 2019). Some of these
MALT1 substrates, such as the deubiquitinases A20 andCYLD (Staal et al., 2011; Coornaert et al., 2008), and
the mRNA-destabilizing proteins Regnase-1, Roquin-1, and Roquin-2 (Jeltsch et al., 2014; Uehata et al.,
2013) are well-known critical negative regulators of pro-inflammatory gene expression whose cleavage is
believed to further fine-tune TCR-induced gene expression. Importantly, inhibition of MALT1 enzymatic ac-
tivity does not influence its scaffolding function, and downstream IkB kinase activation is therefore not
affected (Bardet et al., 2018). In fact, specific inhibition of MALT1 enzymatic activity revealed a unique tran-
scriptional fingerprint of MALT1 protease activity, indicating that the proteolytic activity of MALT1 can
regulate signaling pathways well beyond NF-kB (Bardet et al., 2018).
MALT1 proteolytic activity is essential to drive T cell survival and expansion (Bardet et al., 2018). Similarly,
MALT1 proteolytic activity is essential for the survival and proliferation of certain cancer cells, including
ABC-type diffuse large B cell lymphoma and mantle cell lymphoma (Juilland and Thome, 2016). Moreover,
MALT1 inhibition may also indirectly decrease tumor growth by interfering with the immune-suppressive
function of Tregs (Di Pilato et al., 2019; Rosenbaum et al., 2019). Therefore, the therapeutic potential of
MALT1 inhibition in autoimmune disease and cancer has raised a lot of interest and led to the development
of potent small compound MALT1 inhibitors (Bardet et al., 2018). Several preclinical studies already
showed a protective effect of pharmacological MALT1 inhibition in murine models of multiple sclerosis
(Mc Guire et al., 2014), arthritis (Martin et al., 2020b), lymphoma (Fontan et al., 2012; Nagel et al., 2012;
Dai et al., 2017; Jacobs et al., 2020), and glioblastoma (Jacobs et al., 2020). Noteworthy, a first-in-human
phase I clinical study in participants with relapsed/refractory B-cell non-Hodgkin lymphoma and chronic
lymphocytic leukemia has recently been initiated (https://clinicaltrials.gov/ct2/show/NCT03900598). AiScience 23, 101557, October 23, 2020 ª 2020 The Author(s).





Articlemajor concern was, however, raised by several independent studies showing that knock-in mice constitu-
tively expressing a catalytically inactive MALT1 ‘‘protease-dead’’ mutant (Malt1-PD mice) rapidly develop
lethal autoimmune inflammation inmultiple organs (Gewies et al., 2014; Jaworski et al., 2014; Yu et al., 2015;
Bornancin et al., 2015; Demeyer et al., 2019; Martin et al., 2019). This was somewhat surprising because a
previous study had shown that pharmacological inhibition of MALT1 in mice for up to 3 weeks does not
cause any side effects (Mc Guire et al., 2014). One major difference, however, between the genetic models
and inhibitor treatment is that germline Malt1-PD mice lack protease activity at conception or at a very
young age, whereas MALT1 inhibitor treatment is done in adult life. In this context, the severe reduction
in thymic Tregs in Malt1-PD mice, which are mostly formed at young age (Fontenot et al., 2005), has
been suggested to be at the origin of the severe autoimmune phenotype of these mice (Jaworski et al.,
2014; Gewies et al., 2014; Demeyer et al., 2019; Baens et al., 2018). However, recent studies showed that
MALT1 protease activity is also critical for maintaining Treg function (Cheng et al., 2019; Rosenbaum
et al., 2019), implicating a risk for autoimmunity when MALT1 protease activity is only lost in adulthood.
To have a clear view on the safety of long-term inhibition of MALT1 in adults, we have therefore generated
a full-body tamoxifen-inducibleMalt1-i-PD mouse model, which allowed us to monitor the effect of MALT1
inactivation in adult mice for up to 6 months.RESULTS AND DISCUSSION
Long-Term Inducible MALT1 Inactivation in Adult Mice Decreases Tregs Without Increasing
Effector T Cell Activation
To obtain a full-body tamoxifen-inducible Malt1-i-PD mouse model, we first generated Malt1PD/FL or
Malt1+/FL mice with a tamoxifen-inducible Cre-ERT2 in one Rosa26 allele (Hameyer et al., 2007) and a
LoxP-stop-LoxP (LSL)-RFP reporter for Cre activity in the other Rosa26 allele (Luche et al., 2007) (Figure 1A).
Upon tamoxifen administration, the floxed third exon of the Malt1FL allele and the floxed stop cassette of
the RFP reporter are removed by Cre-mediated recombination. In this way we obtainedMalt1+/ (= control)
and Malt1PD/- (= Malt1-i-PD) mice with RFP+ cells representing cells in which Cre-ERT2 was active. Mice
received tamoxifen for 5 days via oral gavage and were then kept on tamoxifen containing feed to prevent
repopulation byMalt1+/FL orMalt1PD/FL bonemarrow-derived cells. Tomonitor the efficiency of Cre recom-
bination, RFP expression was assessed in blood cells at several time points following the start of tamoxifen
treatment. After 2–3 months the majority of mice had 70% to 85% RFP+ blood cells (Figure 1B). Malt1-i-PD
mice were sacrificed after 6 months tamoxifen treatment, andmost mice had up to 90% or more CD3+ RFP+
cells in their spleen at this endpoint (Figure 1C). Mice showing less than 70% RFP+ cells were excluded from
the analysis in subsequent experiments. MALT1 protease deficiency inMalt1-i-PDmice could be confirmed
by the lack of CYLD, BCL10, and HOIL-1 cleavage in phorbol 12-myristate 13-acetate (PMA)/ionomycin-
stimulated splenocytes (Figure 1D).
Germline inactivation of MALT1 protease activity inMalt1-PD mice is associated with a severe reduction of
Tregs and activation of CD4+ and CD8+ T cells, leading to multi-organ inflammation (Jaworski et al., 2014;
Gewies et al., 2014; Bornancin et al., 2015; Demeyer et al., 2019). In our study, Malt1-i-PD circulating Treg
levels were already decreased upon 1 week tamoxifen treatment and reached about 30% of the levels pre-
sent in control mice after 6 months (Figure 1E). However, despite this significant drop in Tregs, blood CD4+
and CD8+ T cell activation remained unaltered between control and Malt1-i-PD mice (Figures 1F and 1G).
At endpoint,Malt1-i-PD and control mice had similar amounts of thymic and splenic CD4+ and CD8+ T cells
(Figures 2A and 2C). However, the amount of thymic Tregs and splenic Tregs had dropped to 25% and 30%,
respectively, compared with control mice (Figures 2B and 2D). Also, Treg expression of the functionality
markers CTLA4 and TNFR2 was severely reduced upon MALT1 inactivation (Figure 2E), which is in agree-
ment with the described role of MALT1 protease activity in TCR-induced CTLA4 expression in Tregs (Rose-
nbaum et al., 2019). Importantly, the significant drop in CTLA4- and TNFR2-expressing splenic Tregs in
Malt1-i-PD mice did not result in overt splenic CD4+ and CD8+ T cell activation (Figure 2F). Moreover,
the number of TNF-, IL-2-, and IFN-g-producing CD4+ T cells was strongly reduced upon long-term
MALT1 inactivation (Figure 2G). Similar results were obtained for CD8+ T cells, with the surprising excep-
tion for IFN-g-producing CD8+ T cells, which were not altered (Figure 2H). Importantly, the reduction in
IFN-g-producing CD4+ T cells upon long-term inducible MALT1 inactivation is in strong contrast to the in-
crease in IFN-g-producing CD4+ T cells described in constitutive germline Malt1-PD mice (Jaworski et al.,
2014; Demeyer et al., 2019; Martin et al., 2019). Total B cell levels were similar at endpoint (Figure 3A), but
the frequency of MZ B cells was reduced in Malt1-i-PD mice (Figure 3B), which is similar to the previously
described drop inMalt1-PDmice (Demeyer et al., 2019; Gewies et al., 2014; Bornancin et al., 2015; Yu et al.,2 iScience 23, 101557, October 23, 2020
Figure 1. Long-Term Inducible MALT1 Protease Inactivation Reduces Circulating Treg Levels without Changing the Activation Status of CD4+ and
CD8+ T Cells
(A) Strategy to generate Malt1-i-PD mice.
(B) Frequency of RFP+ alive cells in blood of Malt1-i-PD and control mice at several time points after starting tamoxifen treatment.
(C) Frequency of living RFP+ splenocytes, CD3+, CD4+, and CD8+ splenic T cells in Malt1-i-PD and control mice after 6 months tamoxifen treatment.
Excluded = 3 mice with less than 70% RFP+ alive splenocytes that were excluded for subsequent analysis.
(D) Immunoblot for CYLD, HOIL-1, and cleaved BCL10 on splenocyte extracts of control (C1 and C2) and two different Malt1-i-PD mice (i-PD1 and i-PD2)
stimulated in vitro with PMA and ionomycin (PMA/IO) for 1.5 h to activate MALT1. Frequency of RFP+ splenocytes of these mice is indicated.
(E–G) (E) Frequency of Tregs; (F) naive, effector memory (TEM) and central memory (TCM) CD4+ T cells; and (G) CD8+ T cells in blood before and at several
time points after starting tamoxifen treatment.
(B, C, and E–G) Data (control: n = 7 andMalt1-i-PD: n = 8) obtained by flow cytometry, presented as mean G SEM and statistical significance: unpaired two-
tailed Student’s t test (**p < 0.01; ****p < 0.0001). All data are representative for two independent experiments.
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Figure 2. Long-Term Inducible MALT1 Protease Inactivation Reduces Thymic and Splenic Treg Levels Without Changing the Activation Status of
Splenic CD4+ and CD8+ T Cells
Malt1-i-PD (n = 4) and control (n = 7) mice were treated with tamoxifen for 6 months, and thymocytes were analyzed at endpoint by flow cytometry.
(A and B) Frequency of (A) CD4-CD8-, CD4+CD8-, CD4-CD8+, and CD4+CD8+ cells and (B) Tregs (Foxp3+CD4+CD8- T cells).
Malt1-i-PD (n = 6) and control (n = 5) mice were treated with tamoxifen for 6 months, and splenocytes were analyzed at endpoint by flow cytometry.
(C–H) (C) Frequency of CD3+, CD4+, and CD8+ T cells; (D) Tregs (CD25+Foxp3+CD4+ T cells); (E) Tregs expressing TNFR2 or CTLA4; (F) naive, TEM, TCM
CD4+, and CD8+ T cells; (G) CD4+ T cells expressing IL-2, TNF, or IFN-g; and (H) CD8+ T cells expressing IL-2, TNF, or IFN-g.
Data presented as mean G SEM and statistical significance: unpaired two-tailed Student’s t test (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).





Article2015; Jaworski et al., 2014; Baens et al., 2018). There were no significant differences in the amount of mono-
cytes and different DC populations between control and Malt1-i-PD mice (Figure 3C). Together, these re-
sults clearly show that long-term inducible inactivation of MALT1 protease activity in adult mice mainly af-
fects the lymphocyte compartment of the immune system. Most importantly and in contrast to constitutive
MALT1 protease inactivation by germline engineering, long-term MALT1 protease inactivation in adult
mice does not lead to the activation of CD4+ and CD8+ T cells in blood or spleen, despite significantly
reduced Treg levels.
Long-Term Inducible MALT1 Inactivation in Adult Mice Does Not Cause Systemic
Inflammation
In contrast to the severe and rapid body weight loss that was previously observed in constitutive Malt1-PD
mice (Demeyer et al., 2019; Yu et al., 2015; Jaworski et al., 2014; Gewies et al., 2014; Bornancin et al., 2015),
only a mild reduction in body weight was observed in male, but not female, Malt1-i-PD mice at endpoint
(Figure 4A). Also, Malt1-i-PD mice did not develop severe ataxia that was previously observed in constitu-
tiveMalt1-PDmice. In addition, whereas constitutiveMalt1-PDmice were reported to have high serum IFN-
g and TNF levels (Gewies et al., 2014; Demeyer et al., 2019), Malt1-i-PD mice only showed a very mild in-
crease in TNF serum levels and no significant difference for IFN-g, IL-5, IL-10, IL-13, IL-17, and KC (Fig-
ure 4B). Jaworski et al. reported IgE and IgG1 autoantibodies reactive against stomach antigens in consti-
tutive Malt1-PD mice (Jaworski et al., 2014), whereas Martin et al. reported elevated IgE and IgG1
antibodies reactive against bacterial and food antigens (Martin et al., 2019), although these were not essen-
tial for the development of autoimmune inflammation in Malt1-PD mice. In our study, no autoantibodies
against specific nuclear and cytoplasmic antigens could be detected in serum from Malt1-i-PD mice (Fig-
ure S1). Together, these results clearly show that, in contrast to constitutiveMALT1 protease inactivation by
germline engineering, long-term inducible inactivation of MALT1 protease activity in adult mice does not
cause systemic inflammation, which is consistent with the absence of effector T cell activation.
Long-Term Inducible MALT1 Inactivation in Adult Mice Induces Tertiary Lymphoid Structures
in Specific Tissues
Constitutive Malt1-PD mice rapidly develop lethal multi-organ inflammation (Jaworski et al., 2014; Gewies
et al., 2014; Bornancin et al., 2015; Demeyer et al., 2019; Martin et al., 2019). In contrast, Malt1-i-PD mice
looked healthy after 6 months MALT1 inactivation. Spleen size was similar in both Malt1-i-PD and control
mice (Figure 4C), and macroscopic examination of several other organs also did not show any clinical signs
of disease. H&E-stained tissue sections did not reveal inflammation in salivary gland, colon, and liver (Fig-
ure 4D). However, almost all Malt1-i-PD mice suffered from increased immune cell infiltration in the stom-
ach (Figures 4E and 4G) and lungs (Figures 4F and 4H). It should be mentioned that some control mice also
displayed minor immune cell infiltration in stomach and even more in lungs, which may reflect their rela-
tively advanced age. Some of the immune cell infiltrates in Malt1-i-PD mice resembled tertiary lymphoid
structures (Pipi et al., 2018), which was further supported upon staining for B (B220) and T cells (CD3) (Fig-
ures 4I and 4J). Especially in lungs, a separate B cell zone, which is characteristic for inducible bronchus-
associated lymphoid tissue formation (Woodland and Randall, 2004), could be observed (Figure 4J). It
should be mentioned that stomach and lung inflammation has been described in the case of constitutive
Malt1-PD mice (Jaworski et al., 2014; Gewies et al., 2014; Bornancin et al., 2015; Yu et al., 2015; Demeyer
et al., 2019). Moreover, mice with a Treg-specific loss of MALT1 protease function also suffer from lung
inflammation (Cheng et al., 2019). Together, these data demonstrate that, in contrast to the lethal multi-
organ inflammation observed upon germline MALT1 protease inactivation, long-term inducible inhibition
of MALT1 protease activity in adult mice is only associated with local immune cell infiltration in stomach and














Figure 3. Long-Term Inducible MALT1 Protease Inactivation Reduces MZ B Cell Levels and has No Effect on
Monocytes and Different DC Populations
Malt1-i-PD (n = 7) and control (n = 5) mice were treated with tamoxifen for 6 months, and splenocytes were analyzed at
endpoint by flow cytometry.
(A–C) Frequency of (A) total B cells, (B) FO B cells and MZ B cells, and (C) monocytes and different DC populations. Data
obtained by flow cytometry, presented as mean G SEM and statistical significance: unpaired two-tailed Student’s t test
(*p < 0.05; **p < 0.01). Representative flow cytometry plots showing gating strategy and individual B cell frequencies are




ArticleIn conclusion, our data indicate that long-term inhibition of MALT1 proteolytic activity in adult life is rela-
tively safe and does not lead to destructive autoimmune inflammation as previously described upon germ-
line inactivation of MALT1. These discrepancies most likely reflect the known key role of MALT1 proteolytic
activity in thymic Treg development early during life, whereas peripheral Treg generation has been shown
to be less MALT1 dependent (Brustle et al., 2015). In addition, MALT1 protease inhibition results in reduced
cytokine production by T cells in the periphery, which might lead to a new equilibrium between residual
Tregs on one side and lower cytokine-producing T cells on the other side. There is still a caveat of potential
local autoimmunity in lungs and stomach upon MALT1 inhibition, which may reflect a specific role for
MALT1 in immune tolerance toward locally displayed antigens. Interestingly, a recent study in rat and
dog (Martin et al., 2020b) reported decreased Treg numbers and immune infiltration in specific organs,
but no ataxia and lethal autoimmunity upon prolonged treatment with a novel MALT1 inhibitor (MLT-
943), which is in line with our data. Nevertheless, despite an excellent selectivity profile of the used
MALT1 inhibitor, it cannot be fully excluded that off-target effects of the inhibitor contribute to the
observed side effects in the study of Martin et al. Our data with Malt1-i-PD mice, which do not suffer
from off-target effects and show that prolonged and specific MALT1 targeting is only associated with
mild immune cell infiltration in certain organs (stomach and lungs), therefore indicate that studies using
different classes of compounds with improved specificity deserve further evaluation. Going forward, the
evaluation of side effects of different classes of small compound inhibitors of MALT1 for the treatment
of autoimmune inflammation or cancer should therefore especially focus on these tissues that show6 iScience 23, 101557, October 23, 2020
Figure 4. Long-Term Inducible MALT1 Protease Inactivation is Associated with Local Immune Cell Infiltration in Stomach and Lungs
Malt1-i-PD and control mice were treated with tamoxifen for 6 months, and analyzed at endpoint.








(B) Serum cytokine concentration of Malt1-i-PD (n = 12) and control (n = 11) mice.
(C) Representative picture of the spleen of control and Malt1-i-PD mice.
(D) Representative picture of H&E staining of salivary gland (control: n = 10 and Malt1-i-PD: n = 11), colon (control: n = 6 and Malt1-i-PD: n = 6), and liver
(control: n = 10 and Malt1-i-PD: n = 12).
(E and F) (E) Representative picture of different degrees of immune cell infiltration based on H&E staining of stomach and (F) lung from different control (n =
10) and Malt1-i-PD (n = 11) mice. Different degrees of immune cell infiltration (indicated with an asterisk): none (), minor dispersed infiltration (+), multiple
large infiltrations (++), and infiltrations resembling tertiary lymphoid organs (+++).
(G and H) (G) Number of Malt1-i-PD and control mice showing the indicated degrees of stomach and (H) lung immune cell infiltration.
(I and J) (I) Representative picture of anti-B220 and anti-CD3 staining of stomach (n = 3) and (J) lung (n = 3) tissue sections from control andMalt1-i-PD mice
with infiltrations resembling tertiary lymphoid organs (+++).
Scale bars, 100 mm in (D–F) and (I–J); (A and B) mean G SEM and statistical significance: unpaired 2-tailed Student’s t test (*p < 0.05; **p < 0.01). All data are
representative for two independent experiments.




Articleinflammation in our mouse model and in the models used by Martin et al. Similar immune-related adverse
effects have been described for immune checkpoint inhibitors targeting CTLA4 (Friedman et al., 2016;
Johncilla et al., 2019), which could be related to the observed decrease in CTLA4-expressing Tregs
upon inducible MALT1 inhibition. Management strategies developed for those side effects of immune
checkpoint inhibition could potentially also be useful to mitigate the risks of MALT1 protease inhibition
(Brahmer et al., 2018; Friedman et al., 2016). The here-described inducible mouse model for MALT1 target-
ing is unique, in the sense that it allows to follow-up mice for a much longer time than possible with small
compound MALT1 inhibitors that need daily treatment. Such prolonged studies are essential to increase
the successful translation of preclinical mouse studies to patients. While the original enthusiasm of big
pharmaceutical companies in therapeutic targeting of MALT1 was strongly tempered by multiple studies
reporting a severe autoimmune phenotype of constitutive Malt1-PD mice, the results described here can
be expected to stir a renewed interest in the development of small compound MALT1 inhibitors for several
autoimmune diseases and cancers.Limitations of the Study
Lack of lethal autoimmunity in ourMalt1-i-PDmice could still be due to the incomplete inactivation of MALT1.
However, partial MALT1 inactivation in our mice mimics pharmacological targeting (Martin et al., 2020a).
Conceptually our model is therefore very relevant in the context of therapeutic targeting of MALT1 with small
compound inhibitors. Importantly, partial inactivation is what one also observes with most small compounds
in vivo, exposure of which does not result in a complete and continuous inhibition due to the pharmacokinetic
profile of the compound. In addition, there are several partial allosteric inhibitors that only show partial inhi-
bition, known as maximal efficacy. This is very well known in the case of GPCRs (Verespy et al., 2016), but also
exists for other enzymes such as proteases (Conn et al., 2009). It should be stressed that 2 to 3months after the
start of tamoxifen treatment, the number of RFP+ cells in the blood is for most mice between 70% and 85%
(Figure 1B). Moreover, several mice included for endpoint analysis after 6 months had up to 90% RFP+
T cells (Figure 1C). (The level of inhibition in T cells is the most important because disease development in
Malt1-PD mice was previously shown to be driven by defective MALT1 activity in T cells, Demeyer et al.,
2019). Moreover, the above level of MALT1 inactivation clearly reduced the number of IL-2-, TNF-, and IFN-
g-producing CD4+ T cells (Figure 2G), which is known to be dependent on MALT1 proteolytic activity (Bardet
et al., 2018). Last but not least, MALT1-dependent CYLD, HOIL-1, and BCL10 cleavage was completely abol-
ished in splenocytes isolated fromMalt1-i-PDmicewithmore than 70% RFP+ cells (Figure 1D). Together, these
data illustrate that the obtained level of MALT1 inactivation is sufficient to prevent a MALT1-dependent bio-
logical response. In future studies, it will be of interest to determine the in vivo impact of this specific inhibition
of MATL1 protease activity in Malt1-i-PD mice in an autoimmune disease model.
For our experiments we used specific pathogen-free (SPF) mice that might have a different immune status
compared with mice housed in a conventional environment. However, a conventional mouse facility suffers
from several unknown environmental factors that differ from laboratory to laboratory, which can seriously
affect results and hamper reproducibility. SPF conditions have therefore been the standard in most mouse
facilities, including ours, for many years. Moreover, we wanted to compare the results of Malt1-i-PD mice
with previously reported data with constitutiveMalt1-PDmice that were kept in an SPF facility. Importantly,
although both mouse lines were kept in SPF conditions, we could show that Malt1-i-PD mice do not phe-






Further information and requests for resources and reagents should be directed to and will be fulfilled by
the Lead Contact, Rudi Beyaert (Rudi.Beyaert@irc.vib-ugent.be).
Materials Availability
All mouse lines and reagents generated in this study are available from the Lead Contact with a completed
Materials Transfer Agreement.
Data and Code Availability
This study did not generate large-scale datasets. Raw data of this article are available from the lead contact
upon request.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
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Malt1-/-, Malt1FL/FL and Malt1PD/PD C57Bl/6 mice have been described previously (Demeyer et al., 2019). Malt1-
i-PD mice and control mice were respectively Malt1PD/FL and Mal1t+/FL C57Bl/6 mice with a tamoxifen-
inducible Cre-ERT2 transgene in one Rosa26 allele (Hameyer et al., 2007), and a LoxP-stop-LoxP (LSL) RFP 
reporter gene in the other Rosa26 allele (Luche et al., 2007). All mice were maintained under specific-
pathogen free conditions and fed ad libitum at the animal house of the VIB/UGent Center for Inflammation 
Research. Experiments were carried out in accordance with the UGent ethical guidelines and approved by 
the local ethical committee for mouse experiments of the VIB-Ghent University Faculty of Sciences (approval 
numbers EC 2015-031, EC2019-081 and EC2019-082). Equal results were obtained with male and female mice 
unless otherwise specified. 
Single cell suspensions and stimulation 
Spleens and thymi were mechanically disrupted with the plunger of a syringe and filtered over a 70 µm cell 
strainer. For the isolation and analysis of DCs, splenocytes were cut in small pieces and incubated at 37°C for 
30 minutes in RPMI 1640 containing Liberase TM (Roche, Mannheim, Germany) and DNase I (Roche). All 
single cell suspensions were subjected to red blood cell lysis with ACK lysis buffer (Lonza). 
To assess intracellular cytokine production, spleen single cell suspensions were cultured in complete medium 
(RPMI 1640 medium supplemented with 10% FCS, sodium pyruvate, L-glutamine, antibiotics and β-
mercaptoethanol) and stimulated with PMA (50ng/ml), ionomycin (500ng/ml) and brefeldin A (1µg/ml) for 4 
hours at 37°C and 5% CO2. 
To assess MALT1 protease activity, spleen single cell suspensions were cultured in complete medium and left 
unstimulated or stimulated with PMA (200ng/ml) and ionomycin (1µM) for 90 min at 37°C and 5% CO2. 
Immunoblot analysis 
Splenocytes were lysed in 50 mM Hepes pH 7.6, 250 mM NaCl, 5 mM EDTA, and 0.5% (vol/vol) NP-40, plus 
phosphatase and protease inhibitors. Lysates were cleared by centrifugation for 15 min at 14,000 rpm and 
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4°C. Protein concentration was measured by Bradford protein assay (Bio-Rad) and 5x Laemmli buffer (250 
mM Tris-HCl pH 8, 10% SDS, 50% glycerol, 0.005% bromophenol blue, 25% β-mercaptoethanol) was added to 
the lysates. Equal amounts of protein were separated by 8% or 10% SDS–PAGE and analyzed by semi-dry 
immunoblotting and detection via enhanced chemiluminescence (Perkin-Elmer Life Sciences). The antibodies 
that were used are anti-BCL10 cleavage-specific (gift from Thijs Baens, Cistim Leuven vzw, Leuven, Belgium), 
anti-CYLD (sc-74435, Santa Cruz), anti-HOIL1 (sc365523, Santa Cruz), anti-β-actin-HRP (sc-47778, Santa Cruz), 
HRP-conjugated anti-mouse and anti-rabbit IgG antibody (Thermo Fisher Scientific 31432 and 31464).  
Flow cytometry 
Splenocytes, thymocytes and blood cells were analyzed with a LSRII or a Fortessa 5 flow cytometer (BD 
Biosciences) and FlowJo Software (Treestar, Inc, Ashland, Ore) was used for data analysis. Cells were stained 
for 20 min at 4°C with master mix containing a fixable live/dead dye eFluor 506 or eFluor780, FC block anti-
CD16/CD32 and antibodies against surface antigens. Cells were analyzed unfixed or fixed for 30 min at 4°C 
with the BD Cytofix/cytoperm Kit or the eBioscience Foxp3/Transcription Factor staining buffer set. After 
fixing, intracellular antigens were stained by adding the corresponding antibodies in the permeabilization 
solution from the corresponding fixative buffer set for 30 min at 4°C. Antibodies were purchased from BD 
Biosciences, eBioscience, Thermo Fisher Scientific or Tonbo Bioscience. The following antibodies were used 
CD3 (145-2C11 or 17A2), CD4 (RM4-5 or GK1.5), CD8 (53-6.7), CD25 (PC61), CD44 (IM7), CD62L (MEL-14), 
CD11b (M1/70), CD11c (N418), FoxP3 (FJL-16s), TNFR2 (TR75-89), CTLA4 (UC10-4B9), IL-2 (JES6-5H4), IFN-γ 
(XMG1.2), TNF (MP6-XT22), CD19 (1D3), CD45R/B220 (RA3-6B2), CD21/CD35 (4E3), CD23 (B3B4), Siglec H 
(440c), Ly6-C (AL-21), NKp46 (29A1.4), Ly6-G (1A8), MHCII (M5/114.15.2), CD172a (P84). 
Histology 
Stomach, lungs, salivary glands, colon and liver were fixed with 4% paraformaldehyde and imbedded in 
paraffin. Sections (5 µm) were stained with haematoxylin and eosin. Scoring of immune cell infiltration in 
lungs and stomach was done blinded. Lung and stomach sections were stained with anti-CD3 (A0452, Dako-
Agilent Technologies) or anti-B220 (RA3-6B2, eBioscience) and counterstained with haematoxylin. Images 
(100x magnification) were acquired with a BX51 discussion microscope (Olympus) using an objective lens with 
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N.A. 1.0. The 100 µm scale bar was added with Fiji.  
Cytokine detection in blood 
Blood samples were collected for serum preparation and the levels of IL-5 (171-G5006M), IL-10 (171-
G5009M), IL-13 (171-G5012M), IL-17 (171-G5013M), KC (171-G5018M), IFN-γ (171-G5017M) and TNF (171-
G5023M) were determined by Bio-Plex (Biorad) according to the manufacturer’s conditions.  
Statistics  
GraphPad Prism 8 software was used for all statistical analysis. Data are represented as means ± SEM. P values 
were calculated by unpaired Student’s t-test, and differences between groups were considered statistically 




Figure S1. Malt1-i-PD mice have no autoantibodies in their serum after 6 months tamoxifen, Related to 
Figure 4. Picture of line immunoassay strips (INNO-LIA ANA Update, Fujirebio) to detect specific antibodies 
from Malt1-i-PD mice. Serum of healthy C57BL/6 mice and serum from a NOD mouse were included as 
negative and positive controls, respectively. Each strip corresponds to an individual mouse. The assay contains 
the following recombinant and natural antigens: SmB, SmD, RNP-A, RNP-C, RNP-70k, Ro52/SSA, Ro60/SSA, 
La/SSB, CenpB, Topo-I/Scl70, Jo-1, ribosomal P, and histones. Nylon strips were incubated with mouse serum 
at a 1:200 dilution. Following washing, a 1:2,500 dilution of alkaline phosphatase-conjugated anti-mouse IgG 
was added (Chemicon). After washing, addition of the chromogen 5-bromo-4-chloro-3-indolyl phosphate 
produced a dark brown color in proportion to the amount of specific autoantibody in the test sample. Sulfuric 
acid was added to stop the color development. 
 
